114 related articles for article (PubMed ID: 18366956)
1. Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival.
Yap YS; Cornelio GH; Devi BC; Khorprasert C; Kim SB; Kim TY; Lee SC; Park YH; Sohn JH; Sutandyo N; Wong DW; Kobayashi M; Landis SH; Yeoh EM; Moon H; Ro J
Br J Cancer; 2012 Sep; 107(7):1075-82. PubMed ID: 22918394
[TBL] [Abstract][Full Text] [Related]
2. PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling.
Moody SE; Schinzel AC; Singh S; Izzo F; Strickland MR; Luo L; Thomas SR; Boehm JS; Kim SY; Wang ZC; Hahn WC
Oncogene; 2015 Apr; 34(16):2061-71. PubMed ID: 24909179
[TBL] [Abstract][Full Text] [Related]
3. Lapatinib for advanced or metastatic breast cancer.
Opdam FL; Guchelaar HJ; Beijnen JH; Schellens JH
Oncologist; 2012; 17(4):536-42. PubMed ID: 22477724
[TBL] [Abstract][Full Text] [Related]
4. Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives.
Milani A; Sangiolo D; Montemurro F; Aglietta M; Valabrega G
Ann Oncol; 2013 Jul; 24(7):1740-1748. PubMed ID: 23585514
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: a proof-of-concept study.
Stebbing J; Payne R; Reise J; Frampton AE; Avery M; Woodley L; Di Leo A; Pestrin M; Krell J; Coombes RC
PLoS One; 2013; 8(5):e62543. PubMed ID: 23667487
[TBL] [Abstract][Full Text] [Related]
6. Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines.
Clay TM; Osada T; Hartman ZC; Hobeika A; Devi G; Morse MA; Lyerly HK
Immunol Res; 2011 Apr; 49(1-3):235-47. PubMed ID: 21136201
[TBL] [Abstract][Full Text] [Related]
7. HER Family Receptors are Important Theranostic Biomarkers for Cervical Cancer: Blocking Glucose Metabolism Enhances the Therapeutic Effect of HER Inhibitors.
Martinho O; Silva-Oliveira R; Cury FP; Barbosa AM; Granja S; Evangelista AF; Marques F; Miranda-Gonçalves V; Cardoso-Carneiro D; de Paula FE; Zanon M; Scapulatempo-Neto C; Moreira MA; Baltazar F; Longatto-Filho A; Reis RM
Theranostics; 2017; 7(3):717-732. PubMed ID: 28255362
[TBL] [Abstract][Full Text] [Related]
8. Emphasising the European Union's Commitment to Cancer Research: a helicopter view of the Seventh Framework Programme for Research and Technological Development.
van de Loo JW; Trzaska D; Berkouk K; Vidal M; Draghia-Akli R
Oncologist; 2012; 17(10):e26-32. PubMed ID: 23104172
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of adjuvant trastuzumab in daily clinical practice.
Matos E; Zakotnik B; Kuhar CG
Radiol Oncol; 2014 Dec; 48(4):403-7. PubMed ID: 25435855
[TBL] [Abstract][Full Text] [Related]
10. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.
Faber AC; Li D; Song Y; Liang MC; Yeap BY; Bronson RT; Lifshits E; Chen Z; Maira SM; García-Echeverría C; Wong KK; Engelman JA
Proc Natl Acad Sci U S A; 2009 Nov; 106(46):19503-8. PubMed ID: 19850869
[TBL] [Abstract][Full Text] [Related]
11. HER-2-directed, small-molecule antagonists.
Arkin M; Moasser MM
Curr Opin Investig Drugs; 2008 Dec; 9(12):1264-76. PubMed ID: 19037833
[TBL] [Abstract][Full Text] [Related]
12. Lapatinib: a sword with two edges.
Kopper L
Pathol Oncol Res; 2008 Mar; 14(1):1-8. PubMed ID: 18409020
[TBL] [Abstract][Full Text] [Related]
13. Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens.
Blackwell KL; Pegram MD; Tan-Chiu E; Schwartzberg LS; Arbushites MC; Maltzman JD; Forster JK; Rubin SD; Stein SH; Burstein HJ
Ann Oncol; 2009 Jun; 20(6):1026-31. PubMed ID: 19179558
[TBL] [Abstract][Full Text] [Related]
14. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
Cameron DA; Stein S
Nat Clin Pract Oncol; 2008 Sep; 5(9):512-20. PubMed ID: 18594499
[TBL] [Abstract][Full Text] [Related]
15. Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabine.
Liu Z; Fusi A; Schmittel A; Tinhofer I; Schneider A; Keilholz U
Cancer Biol Ther; 2010 Nov; 10(9):860-4. PubMed ID: 20855957
[TBL] [Abstract][Full Text] [Related]
16. The emerging role of lapatinib in HER2-positive breast cancer.
Ulhoa-Cintra A; Greenberg L; Geyer CE
Curr Oncol Rep; 2008 Jan; 10(1):10-7. PubMed ID: 18366956
[TBL] [Abstract][Full Text] [Related]
17. Lapatinib: a review of its use in the treatment of HER2-overexpressing, trastuzumab-refractory, advanced or metastatic breast cancer.
Frampton JE
Drugs; 2009 Oct; 69(15):2125-48. PubMed ID: 19791830
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
